Combined photothermal and photodynamic therapy by hyaluronic acid-decorated polypyrrole nanoparticles
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tuan Hiep Tran | - |
dc.contributor.author | Hanh Thuy Nguyen | - |
dc.contributor.author | Thi Thu Phuong Tran | - |
dc.contributor.author | Ku, Sae Kwang | - |
dc.contributor.author | Jeong, Jee-Heon | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Yong, Chul Soon | - |
dc.contributor.author | Kim, Jong Oh | - |
dc.date.accessioned | 2021-06-22T14:03:28Z | - |
dc.date.available | 2021-06-22T14:03:28Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 1743-5889 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/9579 | - |
dc.description.abstract | Aim: To develop a nanoparticle-based platform using polypyrrole and IR-780 for effective combined photothermal and photodynamic therapy. Materials & methods: IR-780 was loaded in a poly(lactic-co-glycolic acid) core, decorated with polypyrrole shells and hyaluronic acid (IPPH). Physicochemical properties and in vitro and in vivo anticancer effects of these nanoparticles were evaluated. Results: The resulting IPPHs were spherical, small and negatively charged. Under near-infrared laser irradiation, the IPPHs generated reactive oxygen species and heat and synergistically improved therapeutic efficacy. The antitumor effects were confirmed by in vitro cellular reactive oxygen species detection and cytotoxicity assays, and in vivo in a xenograft tumor model, with no damage to body organs. Conclusion: Our results indicate the potential of applying IPPH in oncology nanomedicine. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | Combined photothermal and photodynamic therapy by hyaluronic acid-decorated polypyrrole nanoparticles | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Han-Gon | - |
dc.identifier.doi | 10.2217/nnm-2016-0438 | - |
dc.identifier.scopusid | 2-s2.0-85020859155 | - |
dc.identifier.wosid | 000403575000012 | - |
dc.identifier.bibliographicCitation | NANOMEDICINE, v.12, no.12, pp.1511 - 1523 | - |
dc.relation.isPartOf | NANOMEDICINE | - |
dc.citation.title | NANOMEDICINE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1511 | - |
dc.citation.endPage | 1523 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.subject.keywordPlus | LIPID NANOPARTICLES | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | PHOTOSENSITIZER | - |
dc.subject.keywordPlus | NANOCOMPOSITES | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | PLATFORM | - |
dc.subject.keywordPlus | OXIDE | - |
dc.subject.keywordAuthor | hyaluronic acid | - |
dc.subject.keywordAuthor | IR-780 | - |
dc.subject.keywordAuthor | phototherapy | - |
dc.subject.keywordAuthor | polypyrrole | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/nnm-2016-0438 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.